Gelicon300 mg

Gelicon is a lipid-regulating agent (fibric acid derivative) used in the following settings:

Established/FDA-approved uses

• Severe hypertriglyceridemia (Fredrickson Types IV and V hyperlipoproteinemia): Gelicon is indicated in adult patients with very high triglyceride levels who are at risk of pancreatitis and who have not responded adequately to dietary intervention.
• Reduction of cardiovascular risk in Type IIb hyperlipoproteinemia: Gelicon is indicated to reduce the risk of developing coronary heart disease in patients with low HDL-cholesterol together with elevated LDL-cholesterol and triglycerides, who have not responded to weight loss, diet, exercise, and other pharmacologic measures, and who do not have a history of or existing coronary heart disease.

Notes on use

Gelicon is generally not used as a first-line agent for mild-to-moderate hypercholesterolemia; statins are preferred for isolated LDL-cholesterol elevation. Gelicon is not indicated for use in combination with statins due to a well-documented risk of severe myopathy (see Drug Interactions).

Each tablet contains Gemfibrozil as the active pharmaceutical ingredient, commonly available in a strength of 300 mg or 600 mg per tablet, along with pharmaceutically acceptable excipients such as binders, fillers, and film-coating agents.

Gelicon is a fibric acid derivative (fibrate) used to manage severe elevations in blood triglycerides and to improve HDL-cholesterol levels. It works primarily in the liver to alter the way the body produces and clears fat particles (lipoproteins) in the blood.

Gelicon is available orally as tablets and is typically taken twice daily before meals. It is used under medical supervision with periodic monitoring of blood lipids and liver function.

Gelicon belongs to the fibric acid derivatives (fibrates) class of lipid-lowering agents.

Mechanism of action

Gemfibrozil is an agonist of the peroxisome proliferator-activated receptor alpha (PPAR-alpha). Through this receptor, Gemfibrozil:

• Increases the activity of lipoprotein lipase, enhancing the breakdown of triglyceride-rich lipoproteins (VLDL).
• Decreases hepatic synthesis and secretion of VLDL (the main carrier of triglycerides in blood).
• Reduces the synthesis of apolipoprotein C-III, an inhibitor of lipoprotein lipase.
• Increases the synthesis of apolipoprotein A-I and A-II, resulting in an increase in HDL-cholesterol.

Pharmacokinetics

Gemfibrozil is well absorbed orally, with peak plasma concentrations reached within 1-2 hours when taken before meals. It is highly protein-bound (>95%), metabolized in the liver, and eliminated primarily via the kidneys. Its elimination half-life is approximately 1.5 hours.

Gelicon tablets should be swallowed whole with water, approximately 30 minutes before meals (morning and evening). Do not crush or chew unless directed by a physician. Take at the same times each day to maintain consistent blood levels.

The following are well-documented, clinically significant interactions with Gelicon:

• Statins (especially simvastatin, and to a lesser extent other statins): Gelicon inhibits the glucuronidation and hepatic uptake of statins, markedly increasing statin plasma levels and the risk of severe myopathy and rhabdomyolysis. Concurrent use is generally avoided.
• Repaglinide: Gelicon strongly inhibits CYP2C8-mediated metabolism of repaglinide, leading to a significant increase in repaglinide levels and a risk of severe, prolonged hypoglycemia. Concurrent use is contraindicated (see Contraindications).
• Warfarin and other oral anticoagulants: Gelicon potentiates the anticoagulant effect, increasing bleeding risk. Prothrombin time/INR should be monitored closely and anticoagulant dose adjusted if Gelicon is added or withdrawn.
• Colchicine: Combined use may increase the risk of myopathy/rhabdomyolysis, particularly in patients with renal impairment.
• Bexarotene and other drugs metabolized via similar pathways: May have altered levels when combined with Gelicon; use with caution.

Common and serious side effects reported with Gelicon include:

Common

• Dyspepsia (indigestion)
• Abdominal pain
• Diarrhea
• Nausea and vomiting
• Fatigue

Serious (require prompt medical attention)

• Myopathy, myalgia, and rare rhabdomyolysis, especially when combined with statins (see Drug Interactions)
• Cholelithiasis (gallstones) with long-term use, occasionally requiring cholecystectomy
• Elevated liver enzymes/hepatotoxicity
• Rare reports of atrial fibrillation and blood dyscrasias (anemia, leukopenia, thrombocytopenia)

Pregnancy: There are no adequate, well-controlled studies of Gelicon in pregnant women. Gelicon should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. A physician should be consulted before use in pregnancy.

Lactation: It is not known whether Gelicon is excreted in human breast milk. Because of the potential for adverse effects in nursing infants, a decision should be made whether to discontinue nursing or discontinue Gelicon, taking into account the importance of the drug to the mother. Consult a physician before use while breastfeeding.

• Myopathy/rhabdomyolysis: Gelicon can cause myositis-like symptoms; risk is markedly increased with concurrent statin use (see Contraindications and Drug Interactions). Discontinue if myopathy is suspected or if creatine kinase levels are significantly elevated.
• Gallstones: Long-term use has been associated with an increased incidence of gallbladder disease; if suspected, gallbladder studies are indicated and Gelicon should be discontinued if gallstones are found.
• Liver function: Periodic monitoring of liver function tests is recommended; discontinue if abnormalities persist.
• Hematologic effects: Periodic blood counts are recommended during the first 12 months of therapy.
• Discontinue Gelicon if an adequate lipid response is not obtained after 3 months of treatment.

There is limited clinical experience with Gelicon overdose. Reported effects with fibrate overdose may include gastrointestinal symptoms (nausea, vomiting, abdominal pain) and, potentially, effects related to muscle or liver toxicity. There is no specific antidote for Gelicon overdose.

In case of suspected overdose, seek immediate medical attention or contact a poison control center/emergency services. Treatment is supportive and symptomatic; a physician may consider gastric decontamination if presentation is early, and will monitor liver enzymes, kidney function, and creatine kinase as clinically indicated.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Pediatric use: Safety and efficacy of Gelicon have not been established in children; not recommended for pediatric use.
• Elderly: No specific dose adjustment is established for elderly patients, but they may be more susceptible to myopathy; use with close monitoring, particularly given a higher likelihood of concurrent statin use or renal impairment.
• Renal impairment: Contraindicated in severe renal impairment; use with caution and close monitoring in mild-to-moderate impairment.
• Hepatic impairment: Contraindicated in significant hepatic dysfunction, including primary biliary cirrhosis.

Duration of Gelicon therapy is individualized. Lipid response should be evaluated periodically (typically at 3 months); treatment should be discontinued if an adequate reduction in triglycerides is not achieved. Long-term use requires periodic monitoring of liver function and blood counts.

Fibric acid derivatives (Fibrates) / Lipid-regulating agents

Gemfibrozil activates PPAR-alpha, increasing lipoprotein lipase activity and reducing hepatic VLDL production, which lowers triglycerides and raises HDL-cholesterol.

C

Safety and efficacy of Gelicon in pediatric patients have not been established. Gelicon is not recommended for use in children.